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Abstract Influence of nine synthetic peptides from the C-termi- 
nal part of human a-2 interferon (IFN) molecule on growth of a 
human T-lymphoblastoid cell line MT-4 was investigated. It was 
shown that some peptides inhibited the proliferation of MT-4 
cells. It was also found that MT-4 cells expressed specific recep- 
tors on the outer surface of the plasma membrane. All studied 
peptides competed for binding to a common binding site. Antipro- 
liferative activity of the peptides correlated with their length and 
affinity to receptors on the outer membrane of MT-4 cells. 
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2.2. Radioactive reagents 
[~H]thymidine ([3H]TdR) was from Amersham Corp. (England), 
Na~25I (2 x 106 Ci/M specific activity) was from Russian Scientific Cen- 
ter 'Applied Chemistry' (St. Petersburg, Russia). All media, sera and 
other chemicals were from Sigma IUSA). 
2.3. Peptide synthesis 
Peptides were synthesized essentially as described [4] using t-Boc 
protected amino acids. The protected amino acids were coupled accord- 
ing to the N,N'-diisopropylcarbodiimide/1-hydroxybenzotriazole 
(DIC/HOBt) method. The final deprotection was performed with an 
anhydrous hydrogen fluoride/m-cresol (1(1:1l at 0°C for 60 rain. 
All peptides have a HPLC purity not less than 95%. Mass values of 
the peptides were confirmed by fast atom bombardment mass spectral 
analysis. The peptides, their designation and location on the ~-2 IFN 
molecule are shown in Table 1. 
1. Introduction 
Earlier it was shown that several synthetic peptides from the 
C-terminal part of the human c~-2 IFN  molecule possessed 
lFN-l ike antiproliferative activity on human blood lympho- 
cytes in vitro [1,2]. In contrast o the native IFN molecule, these 
peptides were unable to protect cells from viral infection [3] and 
did not affect activity of natural  killer cells [1]. The studied 
synthetic peptides were thus of limited biological activity as 
compared with the original IFN molecule. We considered it 
interesting to study antiproliferative properties of the peptides 
and their influence on tumor cell growth. 
Nine synthetic peptides corresponding to the human IFN 
molecule region of amino acid residues 124-144 were prepared 
to investigate their effect on growth of an IFN-sensit ive human 
lymphoblastoid cell line MT-4 in vitro. To elucidate the molec- 
ular mechanism of the peptide's action we studied their binding 
properties. 
2. Materials and methods 
2.1. Cell line 
A human Tolymphoblastoid cell line MT-4 was kindly donated by 
Dr. B. Asjo (Dept. Virology, Karolinska Institute, Stockholm. Swe- 
den). 
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Abbreviations: IFN, interferon; [3H]TdR, [3H]thymidine; K d, equilib- 
rium dissociation constant; ICs0, concentration of competing ligand 
causing half-maximum displacement; K~, inhibition constant. 
2.4. Cell culture 
Cells were grown in RPMI 1640 medium supplemented with 10% 
fetal calf serum and gentamicin (50 #g/ml). 
2.5. Cell proliJi,ration 
Cell proliferation was assayed by incorporation of [~H]TdR into 
DNA. Briefly, l x 105 cells were incubated in 24-well plate in the pres- 
ence or absence of the synthetic peptides (10 -~ to 10 ~ M) for 24 72 h, 
of them last 4 h with [3H]TdR (1/~Ci/well) added to the cell culture. The 
incubated cells were harvested and their radioactivity was measured in 
a liquid scintillation counter (Rack-Beta LKB-Wallac, Sweden). 
2.6. Labeling O['synthetic peptides 
5yg ofpeptides 124-138 and 127 138 were labeled by the solid phase 
oxidation method using lodogen and Na~:~l (1 mCi) as described [5]. 
The specific activities of the labeled peptides were 2 × 1() ~ Ci/M. 
2. 7. Binding assay 
5 x 10 ~ to 2 × 106 cells per tube were incubated with labeled peptide 
124~138 at a concentration of 10 6 to 10 "~ M for 1 h at 4°C in 100pl 
of 199 medium containing 20 mM of NaN~ and I% bovine serum 
albumin. Alter the incubation, the cells were applied to 10% sucrose 
gradient and centrifuged as described [6]. The cell-bound radioactivity 
was measured in a Rack-Beta gamma-counter (LKB, Sweden). Exper- 
imental data were analysed by the Scatchard method [7]. Nonspecific 
binding was estimated in the presence of 1000-fold molar excess of the 
unlabeled peptide 124-138. 
2.& Competition assay 
MT-4 cells ( 1.5 x 106 per tube) were incubated at a constant concen- 
tration of ~>I-127 138 peptide (8 x 10 -~ M) and at various concentra- 
tions of unlabeled peptides (10 -4 to 10 '~ M) as described above (Section 
2.7.). The inhibition constant (K,) was calculated as described [8] ac- 
cording to the equation: 
K, = ICs. x (1 + F/Kd), 
where F is a molar concentration of peptide ~2sI-127-138, Kd is the 
dissociation constant of the peptide ~251-127 138-receptor complex, and 
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ICs0 is the concentration f the competing ligand causing half-maxi- 
mum displacement of ~251-127-138. 
2.9. Peptide conjugation with dextran 
Conjugation of radiolabeled and unlabeled peptide 127-138 with 
dextran 500 (Pharmacia) (Dx) was carried out by sodium periodate 
method as described [9]. Dextran/peptide molar ratio was 1/1000 (as 
determined using radioactive peptide ]251-127-138). MT-4 cells were 
incubated with the 1251-127 138-Dx conjugates obtained at a peptide 
concentration f 1.8 x 10 -8 M in the absence or presence of 100-fold 
molar excess of unlabeled 127 138-Dx conjugates or free peptide 127- 
138 as described above in Sections 2.7. and 2.8. 
2.10. Treatment of cells with trypsin 
MT-4 cells (2 x 106/ml) were incubated with trypsin (5 mg/ml) 
(Sigma) in 199 medium (Sigma) for 30 min at 37°C. Trypsin activity 
was then blocked by adding a large volume of medium 199 supple- 
mented with fetal calf serum. The cells were washed thrice by centrifu- 
gation and used in binding experiments. As judged from a Trypan blue 
exclusion test, the cell viability after the trypsin treatment was above 
95%. 
3. Results and discussion 
Earlier it was demonstrated that at least four synthetic pep- 
tides corresponding to fragments of the human a-2 IFN amino 
acid sequence between residues 124 and 138 did inhibit the 
proliferation of lymphocytes from normal human blood [1,2]. 
Interestingly, other similar and partially overlapping peptides 
did not affect the cell proliferation [1]. 
Among the growth inhibiting peptides the most pronounced 
effect was observed for peptide 124-138. Trimming of this pep- 
tide from the N-terminus resulted in decreased antiproliferative 
activity (Fig. 1). Growth inhibition effect of the synthetic pep- 
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Fig. 1. Inhibition of MT-4 cell proliferation by synthetic peptides corre- 
sponding to fragments of the human a-2 IFN molecule. No peptides 
were added to culture media in control. Where added, the concentration 
of peptides was 10 -5 M. [3H]Thymidine was incorporated during last 
4 h of 3-day culturing. S.E.M. was calculated from 4 experiments. 
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Fig. 2. Binding of 1251-124-138 peptide to MT-4 cells. (A) Saturation 
curve. Specific binding (line 2) is presented as the difference between 
the total (line 1) and unspecific (line 3) values. (B) Scatchard plot. 
tides was time- and dose-dependent: maximum inhibition of cell 
growth was observed after 72 h of cell culturing at a peptide 
124-138 concentration of 10 -5 M (not shown). Moreover, it 
depended also on peptide length, the longer the peptide the 
more pronounced was the effect (Fig. 1). 
Thus, some of the studied synthetic peptides are character- 
ised by antiproliferative activity as to both normal human lym- 
phocytes [1,2] and tumor lymphocytes of a lymphoblastoid cell 
line MT-4. 
In our previous work [11] it was shown that lymphocytes 
separated from normal human blood express pecific receptors 
of peptide 124-138. Binding characteristics of iodinated peptide 
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Table 1 
Peptide code Amino acid sequence (one-letter code) K i (M) 
134- 144 YSPCAWEWRA 2.7 x 10 v 
124- 144 RITLYLKEKKYSPCAWEWRA 5.3 x 10 v 
129 144 LKEKKYS PCAWEWRA 6.2 x I 0- 7 
129 138 LKEKKYSPCA 5.8 x 10 8 
124- 133 RITLYLKEKK 5.0 x 10 s 
124-138 RITLYLKEKKYSPCA 4.2 x 10 -~ 
125 138 I TLYLKEKKYSPCA 5.8 × 10 ~ 
126 138 TLYLKEKKYSPCA 5.8 × l0 s 
127 138 LYLKEKKYSPCA 4.0 x 10 
124-138 to MT-4 cells (Fig. 2At supports specific character of 
the interaction. Scatchard analysis [7] of the data suggested the 
K d value of 2.02 × 10 s M and the number of binding sites of 
5.01 × 104 per cell (Fig. 2B). 
To decide if the peptides were bound to the same binding 
sites, displacement experiments werer carried out where radio- 
actively labeled peptide 127- 138 competed with unlabeled pep- 
tides for binding sites on MT-4 cells. Iodinated peptide 12% 138 
was found specifically interacted with MT-4 cells (Fig. 3). The 
results of the displacement assay confirmed that all studied 
peptides competed for the same binding sites (Fig. 3), although 
their inhibition constant values were different (Table 1). 
Growth-inhibiting peptides were characterised by smaller K~ 
values as compared with their inactive counterparts. The K~ 
values correlated with peptide-receptor affinity and inhibiting 
potential of the peptides. 
To confirm that the peptide receptors are located on the 
outer membrane of MT-4 cells, bulky conjugates of radiola- 
beled or unlabeled peptide 127 138 with dextran (~251-127 138- 
Dx and 127 138-Dx, respectively) were used. The dimensions 
of the conjugates prevented their penetration into the cell 
through the plasma membrane. To avoid the uptake of the 
conjugate by cells the incubation medium was supplemented 
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with sodium azide. It was found that radiolabeled conjugate 
'251-124-138-Dx was displaced both by unlabeled conjugate 
127 138-Dx (51 + 5% of total ~esI-124 138-Dx binding) and 
free peptide 127-138 (47 + 5% of total 1:51-124~138-Dx bind- 
ing). These results clearly demonstrate that conjugated and free 
peptide 127 138 interact with the same binding sites exposed 
on the outer cell membrane. 
As a first attempt o characterize the peptide receptors which 
probably mediate the inhibitory effect, MT-4 cells were trypsi- 
nized followed by a peptide-binding assay. Trypsin was shown 
to completely destroy the peptide binding sites on MT-4 cells, 
supporting that the sites are trypsin-sensitive. This finding sug- 
gests that the receptors are represented by protein or modified 
protein molecules expressed on the surface of MT-4 cells. 
Further characterization of the peptide receptors and their 
relation to IFN receptors is a subject of separate studies. 
We believe that the synthetic peptides tudied in the present 
work may serve as a useful tool for investigation of tumor cell 
growth and also may be of interest as potential nontoxic anti- 
proliferative agents. 
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